JP2014517078A5 - - Google Patents

Download PDF

Info

Publication number
JP2014517078A5
JP2014517078A5 JP2014517231A JP2014517231A JP2014517078A5 JP 2014517078 A5 JP2014517078 A5 JP 2014517078A5 JP 2014517231 A JP2014517231 A JP 2014517231A JP 2014517231 A JP2014517231 A JP 2014517231A JP 2014517078 A5 JP2014517078 A5 JP 2014517078A5
Authority
JP
Japan
Prior art keywords
compound
disorder
pharmaceutical composition
composition according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014517231A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014517078A (ja
JP6087911B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2011/041866 external-priority patent/WO2012177263A1/en
Application filed filed Critical
Publication of JP2014517078A publication Critical patent/JP2014517078A/ja
Publication of JP2014517078A5 publication Critical patent/JP2014517078A5/ja
Application granted granted Critical
Publication of JP6087911B2 publication Critical patent/JP6087911B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014517231A 2011-06-24 2012-06-22 有機化合物 Active JP6087911B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/US2011/041866 WO2012177263A1 (en) 2011-06-24 2011-06-24 Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
USPCT/US2011/041866 2011-06-24
US201161501207P 2011-06-25 2011-06-25
US61/501,207 2011-06-25
PCT/US2012/043880 WO2012178112A1 (en) 2011-06-24 2012-06-22 Organic compounds

Publications (3)

Publication Number Publication Date
JP2014517078A JP2014517078A (ja) 2014-07-17
JP2014517078A5 true JP2014517078A5 (cg-RX-API-DMAC7.html) 2015-10-01
JP6087911B2 JP6087911B2 (ja) 2017-03-01

Family

ID=47422974

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517231A Active JP6087911B2 (ja) 2011-06-24 2012-06-22 有機化合物

Country Status (13)

Country Link
US (4) US9469625B2 (cg-RX-API-DMAC7.html)
EP (1) EP2723173B1 (cg-RX-API-DMAC7.html)
JP (1) JP6087911B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140036305A (cg-RX-API-DMAC7.html)
CN (1) CN103717069B (cg-RX-API-DMAC7.html)
AU (2) AU2012272680A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013033306A2 (cg-RX-API-DMAC7.html)
CA (2) CA2840373A1 (cg-RX-API-DMAC7.html)
ES (1) ES2627338T3 (cg-RX-API-DMAC7.html)
IL (1) IL230036A (cg-RX-API-DMAC7.html)
MX (1) MX342322B (cg-RX-API-DMAC7.html)
RU (1) RU2610094C2 (cg-RX-API-DMAC7.html)
WO (3) WO2012177263A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists
US11491150B2 (en) * 2017-05-22 2022-11-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2019152680A1 (en) * 2018-01-31 2019-08-08 Flagship Pioneering Innovations V, Inc. Methods and compositions for treating cancer using chrna6 inhibitors
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ-セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
WO2021008565A1 (zh) * 2019-07-16 2021-01-21 清华大学 乙酰胆碱通路调节剂在治疗癌症中的用途
US12599603B2 (en) 2019-09-03 2026-04-14 Intra-Cellular Therapies, Inc. Methods of treatment
EP4238970A1 (en) * 2022-03-03 2023-09-06 InterAx Biotech AG Modulators of ackr3 and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
PE20021019A1 (es) * 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AU2002363250A1 (en) 2001-11-01 2003-05-12 Icagen, Inc. Pyrazole-amides and-sulfonamides
BR0315056A (pt) * 2002-11-01 2005-08-16 Pharmacia & Upjohn Co Llc Compostos tendo tanto atividade agonista nicotìnica de alfa7 quanto atividade antagonista de 5ht3 para o tratamento de doenças do sistema nervoso central
MXPA05007689A (es) * 2003-01-22 2005-09-30 Pharmacia & Upjohn Co Llc Tratamiento de enfermedades con agonistas completos del receptor alfa-7 de nach.
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
CA2525325A1 (en) * 2003-05-01 2004-11-18 Abbott Laboratories Pyrazole-amides and sulfonamides as sodium channel modulators
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
US20060160794A1 (en) 2003-06-12 2006-07-20 Amegadzie Albert K Tachykinin receptor antagonists
WO2009112459A1 (en) 2008-03-11 2009-09-17 Neurosearch A/S Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
US20100179186A1 (en) 2008-10-10 2010-07-15 University Of Kentucky Research Foundation USE OF A NOVEL ALPHA-7 nAChR ANTAGONIST TO SUPPRESS PATHOGENIC SIGNAL TRANSDUCTION IN CANCER AND AIDS
WO2012177263A1 (en) 2011-06-24 2012-12-27 Intra-Cellular Therapies, Inc. Compounds and methods of prophylaxis and treatment regarding nictonic receptor antagonists

Similar Documents

Publication Publication Date Title
RU2014102191A (ru) Органические соединения
WO2020185532A1 (en) Methods of treating cancer with an fgfr inhibitor
JP2014500295A5 (cg-RX-API-DMAC7.html)
JP2014517050A5 (cg-RX-API-DMAC7.html)
JP2017528487A5 (cg-RX-API-DMAC7.html)
JP2016027043A (ja) がんの治療における使用のためのcdk4/6阻害剤およびpi3k阻害剤を含む併用療法
AU2014220377B2 (en) Treatment of graft versus host disease in transplant patients
JP2019515908A5 (cg-RX-API-DMAC7.html)
JP2014513705A (ja) 進行性固形腫瘍の治療方法
RU2020108192A (ru) Терапевтическая комбинация ингибитора тирозинкиназы egfr третьего поколения и ингибитора raf
CN110198716A (zh) 癌症治疗
JP2020521726A5 (cg-RX-API-DMAC7.html)
CN115605194A (zh) 过度炎症综合征的治疗
CN106632383A (zh) 莪术醇衍生物及其制备方法和在抗肿瘤药物中的应用
TWI791430B (zh) 針對具有重度腎功能障礙之癌症患者之治療方法
JP2013543870A5 (cg-RX-API-DMAC7.html)
JP2018525447A5 (cg-RX-API-DMAC7.html)
US20140316156A1 (en) Method of producing therapeutic agent
WO2025167738A1 (zh) 化合物在制备治疗非髓系恶性肿瘤患者的贫血药物中的应用
US9376432B2 (en) Use of VEGFR-3 inhibitors for treating hepatocellular carcinoma
JP2018506534A5 (cg-RX-API-DMAC7.html)
CN114173779A (zh) 对抗ccr4抗体具有抗性的癌症的治疗剂
Yu et al. OA03. 04 efficacy and safety of the novel HER3 directed antibody drug conjugate patritumab deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
CN107375933A (zh) 热休克蛋白70抑制剂在制备阿片类药物镇痛增强剂中的用途
US9446060B2 (en) Method of producing therapeutic agent